Harnessing subtractive genomics for drug target identification in Streptococcus agalactiae serotype v (atcc baa-611 / 2603 v/r) strain: An in-silico approach.

ABSTRACT: Developing a therapeutic target for bacterial disease is challenging. In silico subtractive genomics methodology offer a promising alternative to traditional drug discovery methods. Streptococcus agalactiae infections depend on two crucial criteria: drug-resistance and the existence of virulence factors. It is essential to underline that S. agalactiae strains have emerged to be resistant to several drugs. Hence, there is a need for research on novel drugs and techniques that are potent, economical, productive, and dependable to combat S. agalactiae infections. In this study advanced computational techniques were exploited to examine potential druggable targets exclusive to this pathogen. Our study uncovered 200 non-homologous proteins in S. agalactiae serotype V (Strain ATCC BAA-611/ 2603

SUBMITTER: Chowdhury ARK 

PROVIDER: S-EPMC12370063 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature